tacrolimus
AssetAlso Advagraf, LCP -Tacro, LCP Tacro, LCP-Tacro
Binds FKBP12 to inhibit calcineurin, suppressing T-cell activation and inflammatory cytokine production.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Inflammation
- 16
- Indications
- 755
- Trials
- 6
- Developers
Indications
16Dermatitis, Atopic
Approved, accessdata.fda.gov, 10 Oct 2026
Graft rejection
Approved, ema.europa.eu, 10 Oct 2026
Kidney transplant
Approved, accessdata.fda.gov, 10 Oct 2026
13 more
In the full profile
- Targets and what it contains4
- Owner and partners6
- Trials755
- Evidence for its targets4
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 12 Oct 2026, 27 sources